icad inc. (ICAD): Price and Financial Metrics

icad inc. (ICAD): $1.30

0.02 (+1.56%)

POWR Rating

Component Grades








Add ICAD to Watchlist
Sign Up

ICAD Price/Volume Stats

Current price $1.30 52-week high $4.66
Prev. close $1.28 52-week low $1.05
Day low $1.28 Volume 72,100
Day high $1.34 Avg. volume 152,355
50-day MA $1.34 Dividend yield N/A
200-day MA $1.97 Market Cap 33.08M

ICAD Stock Price Chart Interactive Chart >


  • ICAD scores best on the Value dimension, with a Value rank ahead of 74.49% of US stocks.
  • ICAD's strongest trending metric is Stability; it's been moving down over the last 179 days.
  • ICAD ranks lowest in Momentum; there it ranks in the 15th percentile.

ICAD Stock Summary

  • With a market capitalization of $34,098,185, ICAD INC has a greater market value than only 11.72% of US stocks.
  • With a year-over-year growth in debt of 240.91%, ICAD INC's debt growth rate surpasses 94.11% of about US stocks.
  • Revenue growth over the past 12 months for ICAD INC comes in at -19.43%, a number that bests only 11.61% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to ICAD, based on their financial statements, market capitalization, and price volatility, are SHPW, KRKR, FARO, TACT, and BKYI.
  • Visit ICAD's SEC page to see the company's official filings. To visit the company's web site, go to www.icadmed.com.

ICAD Valuation Summary

  • In comparison to the median Technology stock, ICAD's price/sales ratio is 46.94% lower, now standing at 1.3.
  • ICAD's price/sales ratio has moved down 5.7 over the prior 243 months.

Below are key valuation metrics over time for ICAD.

Stock Date P/S P/B P/E EV/EBIT
ICAD 2023-05-22 1.3 1.1 -2.4 -1.2
ICAD 2023-05-19 1.3 1.1 -2.5 -1.3
ICAD 2023-05-18 1.2 1.0 -2.3 -1.1
ICAD 2023-05-17 1.2 1.0 -2.2 -1.0
ICAD 2023-05-16 1.1 0.9 -2.1 -0.9
ICAD 2023-05-15 1.2 1.0 -2.3 -1.1

ICAD Growth Metrics

    The year over year price growth rate now stands at -81.39%.
  • Its 5 year net cashflow from operations growth rate is now at -29.84%.
  • Its 3 year net income to common stockholders growth rate is now at -39.08%.
ICAD's revenue has moved down $4,788,000 over the prior 15 months.

The table below shows ICAD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 29.262 -11.207 -14.707
2022-06-30 32.267 -10.84 -12.985
2022-03-31 32.518 -10.294 -13.147
2021-12-31 33.638 -9.408 -11.245
2021-09-30 36.282 -8.763 -8.702
2021-06-30 34.05 -8.989 -8.323

ICAD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ICAD has a Quality Grade of C, ranking ahead of 38.2% of graded US stocks.
  • ICAD's asset turnover comes in at 0.555 -- ranking 80th of 186 Medical Equipment stocks.
  • TTOO, IRMD, and DYNT are the stocks whose asset turnover ratios are most correlated with ICAD.

The table below shows ICAD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.555 0.714 -0.737
2021-03-31 0.561 0.728 -0.590
2020-12-31 0.628 0.719 -1.587
2020-09-30 0.653 0.736 -1.431
2020-06-30 0.695 0.752 -1.339
2020-03-31 0.769 0.754 -1.337

ICAD Price Target

For more insight on analysts targets of ICAD, see our ICAD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $24.00 Average Broker Recommendation 1.31 (Strong Buy)

icad inc. (ICAD) Company Bio

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company was founded in 1984 and is based in Nashua, New Hampshire.

ICAD Latest News Stream

Event/Time News Detail
Loading, please wait...

ICAD Latest Social Stream

Loading social stream, please wait...

View Full ICAD Social Stream

Latest ICAD News From Around the Web

Below are the latest news stories about ICAD INC that investors may wish to consider to help them evaluate ICAD as an investment opportunity.

3 High-Reward Stocks Riding the AI Boom

AI will make many companies' businesses much more effective and profitable, so the best AI stocks are very attractive.

Larry Ramer on InvestorPlace | May 18, 2023

iCAD’s ProFound AI Breast Suite Wins U.S. General Services Administration’s AI Healthcare Challenge Award

Company presented portfolio of breast cancer detection, density assessment and risk evaluation solutions at the competition, focused on improving health outcomesNASHUA, N.H., May 18, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its ProFound AI® Breast Suite is a winner of the U.S. General Services Administration’s (GSA) “AI Healthcare Challenge” award. iCAD presented its portfol

Yahoo | May 18, 2023

iCAD, Inc. (ICAD) Q1 2023 Earnings Call Transcript

iCAD, Inc. (ICAD)

Q1 2023 Earnings Conference Call

May 15, 2023, 04:30 PM ET

Company Participants

Linnell Faber - Executive Assistant to CEO

Dana Brown - President and CEO

Eric Lonnqvist - CFO

Conference Call Participants

Per Ostlund - Craig Hallum

Marie Thibault - BTIG

Yale Jen - Laidlaw & Company

Frank Takkinen - Lake Street Capital Markets

Francois Brisebois - Oppenheimer



Good day, everyone, and welcome to the iCAD, Inc. First Quarter 2023 Earnings Call. At this time all participants have been placed on a listen-only mode and we will open the floor for your questions and comments after the presentati...

SA Transcripts on Seeking Alpha | May 16, 2023

Q1 2023 ICAD Inc Earnings Call

Q1 2023 ICAD Inc Earnings Call

Yahoo | May 16, 2023

iCAD Non-GAAP EPS of -$0.14 misses by $0.03, revenue of $5.77M misses by $0.44M

  • iCAD press release (NASDAQ:ICAD): Q1 Non-GAAP EPS of -$0.14 misses by $0.03.
  • Revenue of $5.77M (-23.3% Y/Y) misses by $0.44M.
  • Total Detection and Therapy revenue for the first quarter of 2023 was $5.8 million, a decrease of $1.7 million, or 23%, as compared to the first quarter of 2022.

Seeking Alpha | May 15, 2023

Read More 'ICAD' Stories Here

ICAD Price Returns

1-mo -7.14%
3-mo -52.03%
6-mo -28.57%
1-year -65.97%
3-year -88.93%
5-year -61.88%
YTD -28.96%
2022 -74.58%
2021 -45.45%
2020 69.88%
2019 110.00%
2018 7.56%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!